Filing Flows › Stoke Therapeutics (STOK) › Q2 2025
Stoke Therapeutics (STOK) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Stoke Therapeutics (STOK) reported revenue of $13.8M for the second quarter 2025 (Q2 2025), +186% from a year earlier and -91% from the quarter before. Operating margin was -197.6%, net loss $23.5M (170.0% of revenue).
Stoke Therapeutics, Q2 2025: revenue $13.8M (+186% year over year), operating margin -197.6%, net loss $23.5M, operating cash flow −$25.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.8M | -91% | +186% |
| Operating profit | −$27.3M | -125% | — |
| Net earnings | −$23.5M | -121% | — |
| Operating cash flow | −$25.4M | -119% | — |
What changed
Revenue was $13.8M in Q2 2025, up 186% year over year and down 91% from the previous quarter.
Operating costs exceeded revenue by $27.3M, an operating margin of -197.6%. Total costs grew 20% against revenue growth of 186%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $23.5M, after a profit of $112.9M the previous quarter.
Operating cash flow was −$25.4M. Non-cash charges added back $446K of depreciation and $7.6M of share-based compensation. Working capital and other items used $10.0M. Capital expenditures of $154K exceeded it, leaving free cash flow of −$25.6M.
Questions
What was Stoke Therapeutics' revenue in the second quarter 2025?
Stoke Therapeutics (STOK) reported revenue of $13.8M for the second quarter 2025 (Q2 2025), +186% from a year earlier and -91% from the quarter before.
Was Stoke Therapeutics profitable in the second quarter 2025?
Operating loss was $27.3M (-197.6% of revenue) and net loss $23.5M.
Source: Stoke Therapeutics 10-Q on SEC EDGAR.